


DAPA-HF TRIAL



Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Randomized, parallel group, placebo-controlled trial



Objective: To evaluate dapagliflozin (a sodium-glucose cotransporter 2 [SGLT2] inhibitor) compared with placebo among patients with heart failure and a reduced ejection fraction (HFrEF).

4,744 patients

Inclusion criteria: patients with symptomatic HF; LVEF $\leq 40\%$ NT-proBNP ≥ 600 pg/ml (if hospitalized for HF within last 12 months ≥ 400 pg/ml; if atrial fibrillation/flutter ≥ 900 pg/ml)



Dapagliflozin
10 mg daily
(n = 2,373)



Placebo
(n = 2,371)



PRIMARY OUTCOME

16.3

Cardiovascular death, hospitalization for HF, or urgent HF visit%
HR 0.74; 95% CI 0.65-0.85, P< 0.001

21.2

SECONDARY OUTCOME

9.6

Cardiovascular death %
HR 0.82; 95% CI 0.69 to 0.98

11.5

1.2

Worsening of renal function %
HR 0.71; 95% CI 0.44 to 1.16

1.6

Conclusion: Dapagliflozin vs. placebo was associated with a reduction in cardiovascular deaths and HF events